261 related articles for article (PubMed ID: 31667572)
1. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
[TBL] [Abstract][Full Text] [Related]
2. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
[TBL] [Abstract][Full Text] [Related]
5. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
6. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
7. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
9. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
[TBL] [Abstract][Full Text] [Related]
11. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O; Klingbiel D; Ruhstaller T; Nolè F; Eppenberger S; Oehlschlegel C; Bernhard J; Brauchli P; Hess D; Mamot C; Munzone E; Pestalozzi B; Rabaglio M; Aebi S; Ribi K; Rochlitz C; Rothgiesser K; Thürlimann B; von Moos R; Zaman K; Goldhirsch A;
Ann Oncol; 2017 Feb; 28(2):305-312. PubMed ID: 27998961
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
Horita Y; Nishino M; Sugimoto S; Kida A; Mizukami A; Yano M; Arihara F; Matsuda K; Matsuda M; Sakai A
Anticancer Drugs; 2019 Jan; 30(1):98-104. PubMed ID: 30124494
[TBL] [Abstract][Full Text] [Related]
13. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
17. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
18. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
[TBL] [Abstract][Full Text] [Related]
19. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
[TBL] [Abstract][Full Text] [Related]
20. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]